Mind Medicine MindMed. has filed a patent for a composition that includes the R(-) enantiomer of MDMA or MDA for use in psychotherapeutic treatment. The patent also claims methods for treating medical conditions such as autism and social anxiety disorders, reducing neurotoxicity, hyperthermia, and physical dependence or abuse liability associated with MDMA and MDA. GlobalData’s report on Mind Medicine MindMed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mind Medicine MindMed, Nanoparticle drug conjugates was a key innovation area identified from patents. Mind Medicine MindMed's grant share as of September 2023 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
Composition for psychotherapeutic treatment with r(-) enantiomer of mdma or mda
A recently filed patent (Publication Number: US20230310368A1) describes a composition for use in psychotherapeutic treatment. The composition includes the R(-) enantiomer of MDMA or MDA, which is a specific form of these substances. The R(-) enantiomer of MDMA or MDA can be present in an amount ranging from 10-1000 mg. Additionally, the composition may include a prodrug bound to the R(-) enantiomer, with the prodrug being an amino acid chosen from a specific group.
The composition can be formulated in various ways for administration. It can be in a continual slow-release formulation, allowing for a sustained release of the R(-) enantiomer over time. Alternatively, it can be in an intranasal spray form, providing a convenient method of administration. The composition can also be in a liquid dosage form, such as suspensions, solutions, emulsions, and more. Furthermore, it can be in an oral dosage form, including capsules, films, lozenges, patches, and others.
The patent also describes methods of treating individuals for medical conditions using the composition. The method involves administering an effective amount of the R(-) enantiomer of MDMA or MDA and treating the individual. The administering step can involve a dosage of 10-1000 mg of the R(-) enantiomer, and it can be done daily. The method aims to prevent or reduce side effects associated with racemic MDMA or MDA, such as neurotoxicity, hyperthermia, and dependence/addiction.
In addition to treating medical conditions, the composition and method can be used to enhance psychotherapy. It can induce feelings of well-being, connectivity, trust, love, empathy, openness, and pro-sociality, thereby enhancing the therapeutic bond in any psychotherapy setting.
Furthermore, the patent describes methods of reducing neurotoxicity, hyperthermia, and physical dependence or abuse liability of MDMA and MDA. These methods involve administering the R(-) enantiomer of MDMA or MDA in an effective amount, potentially with a prodrug bound to it.
Overall, this patent presents a composition and methods for using the R(-) enantiomer of MDMA or MDA in psychotherapeutic treatment, with potential applications in various medical conditions and psychotherapy settings. The specific formulations and dosages described aim to reduce side effects and enhance the therapeutic effects of these substances.
To know more about GlobalData’s detailed insights on Mind Medicine MindMed, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
